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ABSTRACT
Background and the purpose of the study: Lamotrigine (LMG) undergoes extensive hepatic 
metabolism upon oral administration and its absorption is affected in the presence of food. 
This study was aimed to develop nanosuspension of LMG and investigate its formulation 
characteristics using L9 orthogonal array. 
Methods: Nanosuspension was prepared using emulsification-solvent diffusion method. All the 
formulations were subjected to in-vitro evaluation and the statistically optimized one was used 
for stability, scanning electron microscopic and differential scanning calorimetric studies. 
Results: Nanoparticles  were  spherical  with  little  surface  adsorbed  drug.  Formulation 
characteristics in terms of size, zeta potential, polydispersity index (PDI), entrapment efficiency 
(EE), drug content and  in vitro drug release were consistent and within their acceptable range. 
All the batches provided a burst release profile during first 1 hr, followed by a controlled release 
extending up to 24 hrs. The values of n in Peppas model ranged between 0.2-0.4 for all the 
formulations indicative of Fickian release mechanism. The formulation remained reasonably 
stable up to 3 months. No interaction was observed among the drug and polymers. 
Major conclusion: Results of in vitro drug release studies suggested that nanosuspension might 
be used as a sustained delivery vehicle for LMG. Statistical analysis revealed that size of the 
nanoparticles was most strongly affected by stabilizer type while EE was influenced by the 
drug-to-polymer ratio.
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INTRODUCTION
Lamotrigine  (LMG),  an  antiepileptic  drug  of 
Phenyltriazine  class,  is  used  for  the  treatment 
of  partial  seizures  and  those  associated  with  the 
Lennox-Gastant syndrome. It is a basic drug (pKa 
5.3) with an intrinsic solubility of 0.17 mg/ml and 
undergoes extensive hepatic metabolism upon oral 
administration (1). Also, its absorption is affected in 
the presence of food (2). Existing formulations of 
LMG provide immediate release with tmax ranging 
from 1.4 to 4.8 hrs and result into a release profile 
with various peaks and troughs. Therefore, it was 
proposed to develop the nanosuspension of LMG 
which  would  improve  its  solubility  and  provide 
the  plasma  concentrations  within  the  therapeutic 
window over a longer period of time. 
Nanosuspensions  are  sub-micron  colloidal 
dispersions of pure drug particles in an outer liquid 
phase. They prolong the contact time of drug thereby 
enhancing its uptake via the GIT, provide the drug 
release  which  is  unaffected  by  GI  variations  and 
have a better stability profile than liposomes. They 
also enhance saturation solubility of the drug as a 
result of improvement in dissolution rate (3-5).
Several  methods  have  been  proposed  for  the 
preparation of polymeric nanoparticles, e.g.  solvent 
evaporation (6), nanoprecipitation (7) and salting-
out (8). These methods suffer from certain potential 
disadvantages, such as the use of toxic solvents, low 
yield,  high  energy  consumption  and  presence  of 
bio-incompatible residual salts (9). Emulsification-
solvent  diffusion  method  is  interesting  for  many 
reasons  such  as:  the  use  of  pharmaceutically 
acceptable  organic  solvents,  high  yields,  good 
reproducibility  and  easy  scale  up  (10).  Eudragits 
have been used extensively for particulate systems 
such  as  microspheres  (11),  pseudolatex  (12)  and 
nanoparticles (11). Their uses in the present study 
stems from the assumption that they interact with 
the  negatively  charged  mucosal  surface  owing  to 
their polycationic nature (13) which would prolong 
the residence of formulation in gastro-intestinal tract 
and render the treatment more effective.
Various factors affecting the properties of nano-
suspension using L9 orthogonal design have been 
reported  (14).  Thus,  objective  of  the  study  was 
to  develop  and  evaluate  the  controlled  release 
nanosuspension of LMG by emulsification diffusion 
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method  and  to  study  various  process  parameters 
affecting their characteristics by using experimental 
design approach.
MATERIAL  AND  METHODS
Material  
Lamotrigine  (LMG),  poly  vinyl  alcohol  (PVA)  and 
poloxamer 188 were obtained as gift samples from 
Glenmark  Pharmaceuticals  Ltd,  Mumbai,  India. 
Eudragit  RLPO  (E-RLPO)  and  Eudragit  RSPO 
(E-RSPO) were obtained from Lupin Research Park, 
Pune, India. Tween 80 was procured from Loba Chemie, 
Mumbai, India. All other chemicals were of analytical 
grade and used without any further purification.
Methods 
Preparation of the nanosuspension 
Nanosuspension was prepared by the emulsification-
diffusion process (4). Triple distilled water (TDW) 
and ethyl acetate were mutually saturated for 10 min 
to achieve initial thermodynamic equilibrium (15). 
Weighed amount of polymer and LMG (as per the 
experimental design) were dissolved in 10 ml of water 
saturated solvent followed by its emulsification with 
20 ml of 5 % (w/v) stabilizer at 2000 rpm for 15 min. 
Then 80 ml of TDW was added to the emulsion with 
subsequent stirring for 15 min to induce diffusion of 
organic solvent into the continuous phase and leading 
to the formation of nanoparticles (10). Organic solvent 
was  removed  by  evaporation  for  approximately 
50  min  under  reduced  pressure  at  30°C.  Each 
experimental  run  was  performed  in  triplicate.
Characterizations of the prepared nanosuspension
Fourier transform infrared (FT-IR) and Differential 
scanning calorimetric (DSC) studies 
FT-IR  spectra  of  LMG  and  its  physical  mixtures 
(1:1) with the polymers were recorded by grinding 
and  dispersing  the  samples  with  micronised  IR 
grade KBr powder. The mixture was dissolved in 
chloroform and casted on a sodium chloride disk, 
and subjected to FT-IR measurement over the range 
of 4000–400 cm-1 with a resolution of 4 cm-1 for 50 
scans (Schimadzu, Model 8400, Japan).  
DSC  studies  were  performed  for  the  pure  drug, 
pure  polymer  and  freeze  dried  sample  (Decibel 
Instruments,  India)  of  the  optimized  formulation. 
The  sample  (~5  mg)  was  weighed  on  aluminium 
pan and heated to 300°C at a rate of 10°C/min and 
the thermogram was recorded (DU-PONT, Model 
9900, USA). An empty aluminum pan was used as a 
reference (16).
Particle size, polydispersity index (PDI) and zeta 
potential (ζ) 
Nanosuspensions were diluted with filtered (0.22 μm) 
ultrapure water and analyzed by photon correlation 
spectroscopy  (PCS)  with  Master  sizer  (Malvern 
Instruments,  UK)  yielding  the  mean  particle 
diameter of the suspension and polydispersity index 
(17). Values  of ζ were assessed by determining the 
electrophoretic mobility of particles using the same 
instrument. The mobility, µ was converted to the 
ζ-potential by Smoluchowski relation (18).
Total drug content (TDC) and entrapment efficiency 
(EE) 
An aliquot (0.5 ml) of the prepared nanosuspension 
was  evaporated  to  dryness.  The  residue  was 
dissolved in methanol and filtered with a 0.45 µm 
filter.  Total  drug  content  was  determined  by  UV 
spectrophotometry  at  λmax  of  309  nm  using  the 
formula:
For the analysis of free dissolved drug (FDD), 2 ml 
of  nanosuspension  was  centrifuged  at  15000  rpm 
at  4°C  (Remi  Instruments,  Mumbai,  India)  for  1 
hr and the supernatant was immediately analyzed 
spectrophotometrically  (λmax  266  nm).  Settled 
nanoparticles were washed three times with 0.1N 
HCl and analysis of combined washings provided 
surface adsorbed drug (SAD). Entrapment efficiency 
was  determined  from  TDC  and  FDD  using  the 
formula:                          
             
In-vitro drug release studies
Dialysis  bag  diffusion  technique  was  used  to 
study  in-vitro  release  of  drug  from  the  prepared 
nanosuspension (19). The formulation (2ml) was then 
placed in the dialysis bag (Sigma Aldrich, Molecular 
Weight  cut  off  12000  Da),  hermetically  sealed  and 
immersed into a 100 ml beaker containing 50 ml of 
the release media maintained at 37±0.5°C and stirred 
at 500 rpm  (Decibel Instruments,  India). Aliquots 
of 5 ml were  with drawn at pre-determined time 
intervals (½, 1, 2, 3, 4, 5, 6, 7, 8 and 24 hrs) and 
immediately  restored  with  the  same  volume  of 
fresh  media  maintained  at  the  same  temperature. 
The study was carried out by buffer change method 
using acidic buffer (0.1 N HCl) of pH 1.2 for the 
first 2 hrs, citrate buffer (pH 4.5) for next 2 hrs and 
phosphate buffer (PB, pH 7.4) for the rest of the 
study period, i.e. 20 hrs. Since LMG has limited 
solubility in PB of pH 7.4 under the conditions 
of  in-vitro  dissolution  studies;  1%  v/v Tween  80 
was used to maintain the sink condition. The drug 
was  analyzed  spectrophotometrically  at  266  nm 
for acidic buffer and at 309 nm for citrate and 
phosphate buffers. Data from in-vitro drug release 
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studies were fitted to various models to study the 
drug release mechanism.
In addition, the optimized formulation was subjected 
to the drug release studies in citrate buffer (pH 4.5) 
for initial 4 hrs and in PB of pH 7.4 with 1% Tween 
80 for the rest of 20 hrs to assess its release properties 
in altered pH conditions due to the presence of food 
in the stomach and as a result to establish its superiority 
over the conventional formulations. 
Scanning electron microscopic (SEM) and stability 
studies 
Scanning  electron  micrographs  (Hitachi  S3400N, 
Japan)  of  the  statistically  optimized  formulation 
were taken to study the size and morphology of the 
prepared  nanoparticles  (18).  For  stability  studies, 
formulation was stored in hermetically closed glass 
vials and kept at 40±2°C/75±5%RH for 3 months. It 
was evaluated for particle size, entrapment efficiency 
and in-vitro drug release studies.
Statistical optimization and analysis 
Experimental variables (amount of polymer, amount 
of drug, types of the stabilizer and polymer) were 
identified  during  preformulation  studies  and 
investigated  at  three  pre-decided  levels  (-1,  0 
and  +1)  using  a  fractional  factorial  design  in  the 
form  of  L9  orthogonal  array.  Classical  approach 
of varying one variable at a time requires a total 
of  81  (34)  experiments.  However,  present  design 
simplified  the  experimental  effort  and  reduced 
the  number  of  experiments to  nine.  Experimental 
runs were performed in randomized sequence and 
signal-to-noise ratio (SNR) was calculated using the 
performance characteristics “smaller-the-better” or 
“larger-the-better”, whichever appropriate (14, 20, 
21). ANOVA was performed for each batch. P values of 
0.05 were considered significant. The formulation 
prepared under statistically optimized experimental 
conditions was utilized for DSC, SEM and stability 
studies. 
RESULTS  AND  DISCUSSION
FT-IR and DSC studies 
Fig. 1 shows the FT-IR spectra of pure LMG and 
its  1:1  mixtures  with  E-RLPO  and  E-RSPO. 
Characteristic  peaks  of  LMG  were  obtained  at 
3445 cm-1, 2353 cm-1
, 1620 cm-1
 and in the range of 
1300-1500 cm-1
 which remained unaffected in the 
presence  of  polymers.  Neither  disappearance  nor 
suppression of the peaks was observed, thus ruling 
out  the  possibilities  of  drug-polymer  interaction. 
Furthermore, FT-IR spectra of the formulation also 
showed peaks in the region of 1300-1500 cm-1
 which 
confirmed loading of drug into the formulation with 
no interactions with the polymer (data not shown). 
As it might be evidenced from DSC studies (Fig. 
2),  pure  LMG  showed  a  sharp  endothermic  peak 
at  217.8°C  with  a  melting  enthalpy  of  116.6  J/g 
while  that  of  E-RSPO  showed  a  relatively  flat 
thermal profile indicative of the amorphous nature 
of the polymer. A weak peak could be detected at 
71.0°C for E-RSPO with a melting enthalpy of –5.4 J/g. 
Variables Level 1(-1) Level 2 (0) Level 3 (+1)
Amount of polymer
(per 50 ml)
200 mg 400 mg 800 mg
Amount of drug
(per 50 ml)
12.5 mg 25 mg 50 mg
Stabilizer type  PVA PLX Tween 80 
Polymer type E-RLPO E- RLPO: 
E-RSPO (1:1)
E-RSPO
Table 1. Control variables with their levels used in experimental 
design
PVA - Poly vinyl alcohol, PLX - Poloxamer 188, E-RLPO - 
Eudragit RLPO, E-RSPO - Eudragit RSPO
Batch code Size (nm)
(Mean ± SD), n=3
Zeta potential
(mV) (Mean ± SD), n=3
PDI (Mean ± SD),
n=3
 %TDC 
(Mean ± SD), n=3
% EE (Mean ± SD), 
n=3
LNP 1 323.5 ± 2.12 21.97 ± 2.59 0.189 ± 0.02 95.23 ± 0.32 71.86 ± 0.58
LNP 2 184 ± 1.41 13.82 ± 2.008 0.553 ± 0.05 96.22 ± 0.54 60.68 ± 0.61
LNP 3 54.5 ± 4.94 0.60 ± 0.008 0.351 ± 0.02 98.57 ± 0.45 52.79 ± 0.44
LNP 4 327.5 ± 3.53 11.43 ± 0.86 0.662 ± 0.04 96.17 ± 0.34 80.80 ± 0.35
LNP 5 60.5 ± 2.12 0.66 ± 0.02 0.403 ± 0.03 97.58 ± 0.44 71.11 ± 1.45
LNP 6 293.5 ± 10.60 16.98 ± 1.69 0.195 ± 0.07 98.85 ± 0.58 64.56 ± 1.004
LNP 7 69.0 ± 1.41 0.79 ± 0.08 0.387 ± 0.025 98.01 ± 0.25 83.72 ± 0.24
LNP 8 477.5 ± 3.53 24.92 ± 0.87 0.203 ± 0.054 97.94 ± 0.466 85.77 ± 0.77
LNP 9 219.5 ± 2.13 14.68 ± 0.26 0.540 ± 0.014 98.02 ± 0.554 73.39 ± 0.2
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None of the peaks of LMG could be detected in 
the thermogram of drug loaded nanoparticles thus 
neglecting  the  possibilities  of  the  presence  of 
crystalline drug in the formulation. A peak, detected 
at 82.6°C, confirmed molecular dispersion of LMG 
in the formulation which is characterized by a single 
Tg that shifts between those of pure drug and polymer 
as a function of drug to polymer ratio in the mixture 
(22, 23). 
Particle size, polydispersity index (PDI) and zeta 
potential (ζ)  
Particle size ranged from 55 nm (Batch LNP3) to 
478 nm (Batch LNP8) and seemed to be affected 
by  relative  viscosity  of  the  polymeric  dispersion 
in  the  presence  of  stabilizers  which  followed  the 
trend: PVA>Poloxamer>Tween (observed visually). 
Batches with Tween as stabilizer (Batches LNP3, 
LNP5 and LNP7) possessed the least particle size 
while those containing PVA (Batches LNP1, LNP6 
and LNP8) had the largest particle size (Table 2). 
PVA  contains  a  number  of  OH  groups,  which 
might  have  formed  hydrogen  bonds  with  the 
solvent  resulting  in  an  increased  viscosity  of  the 
dispersion.  Consequently, the energy applied during 
homogenization might have become insufficient to 
overcome  the  resistive  viscous  forces,  leading  to 
comparatively larger droplets. Besides, PVA forms a 
connected network with the polymer at the interface 
and remains associated despite repeated washings, 
which may be another reason for the formation of 
larger sized nanoparticles (9). On the other hand, 
interactions  between  lipophilic  portions  of  LMG 
with  that  of  Tween  might  be  substantial  for  the 
formation of smaller droplets (5). 
The  difference  in  values  of  PDI  which  ranged 
between 0.189 and 0.662 could be attributed to the 
efficiency of stabilizers, which cover the organic/
aqueous  interface  of  the  emulsion  nanodroplets 
and  prevent  them  form  coalescing  to  each  other. 
Batches  with  PVA  as  stabilizer  provided  better 
PDI values. Presence of sufficient polymer chains 
of PVA might have provided comparatively better 
coverage and therefore, stabilization to the emulsion 
droplets  allowing  a  homogeneous  NP  distribution 
(10). Values of ζ were found to be in the range of 
+0.60 to + 24.92 indicative of stable formulations 
(3). Its significantly wider range indicates that it was 
affected  by  the  variables  considered  in  the  study 
(Table  2). Total  drug  content  for  all  batches  was 
found to be greater than 95%. Entrapment efficiency 
varied from 52.79 to 85.77%, depending upon the 
polymer to drug ratio (Table 2). 
In-vitro drug release studies 
All  batches  were  similar  in  providing  more  than 
98% drug release at the end of 24 hrs; indicative 
of structural homogeneity of the polymeric matrix 
and  uniform  distribution  of  drug  content  (24). 
However,  they  provided  a  burst  release  during 
first 1 hr due to a simultaneous release of surface 
bound  drug  (being  more  than  18%).  It  differed 
significantly among different batches (P<0.05, one 
way ANOVA). Burst phase was, however, followed 
by hydration and swelling of the nano-matrix which 
eventually led to a controlled release profile lasting 
up to 24 hrs. Hydration brings about an increment 
in  the  diffusional  path  length  of  molecules  and 
consequently  the  rate  of  their  diffusion  becomes 
lower (25). Therefore, gaining of controlled release 
profile  and  its  maintenance  could  be  assumed  to 
be  dependent  upon  the  relative  hydration  rate  of 
the polymer and integrity of the hydrated matrix. 
Therefore, superiority of one formulation over the 
other could be established on the basis of avoidance 
of burst release, achievement of a controlled release 
profile  and  its  maintenance  in  a  time  dependent 
manner.
The release rate was found to be mainly affected 
by: polymer to drug ratio (P: D), stabilizer type and 
particle size (Fig. 3, a-c). Formulations containing 
E-RLPO (Batches LNP1, LNP5 and LNP9) possessed 
similar P: D (8: 1) and differed only with respect 
to  stabilizer  type.  However,  burst  effect  provided 
Figure 1. FT-IR spectra: a) LMG, b) LMG+E-RSPO c) LMG+E-
RLPO
Figure  2.  DSC  thermograms:  a)  pure  drug,  b)  E-RSPO 
nanoparticles loaded with LMG,  c) E-RSPO
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Figure 2. DSC thermograms: a) pure drug, b) E-RSPO nanoparticles loaded with LMG, 
c) E-RSPO 
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by  them  followed  the  order  LNP1<LNP9<LNP5. 
Since other three variables (amount of drug, amount 
of  polymer  and  polymer  type)  were  common  for 
each  of  the  above  formulations,  the  only  factor 
responsible could be the stabilizer type, i.e. Tween. 
This  idea  was  strengthened  from  the  finding  that 
other formulations containing Tween (Batches LNP3 
and LNP7) also provided significantly higher burst 
effect (P<0.05, one way ANOVA). Due to surfactant 
activity of Tween, it might have caused fluidization 
of  the  hydrated  matrix  thus  enhancing  its  rate  of 
erosion and exposing the core of nanoparticles to 
the solvent front. Consequently, all the formulations 
containing Tween showed an exceptionally higher 
burst effect.
Formulations containing 1:1 mixture of E-RLPO and 
E-RSPO (Batches LNP2, LNP6 and LNP7) provided 
burst  effect  in  the  order  of  LNP2<LNP6<LNP7. 
The difference between LNP2 and LNP6 was not 
significant (P<0.05, one way ANOVA) which may 
be due to their similar P: D (8: 1) values. LNP7 
showed a significantly higher burst effect (CPR = 
41% in 0.5 hr) in spite of having higher P: D (64: 1) 
due to comparatively lower particle size (69 nm) and 
presence of Tween which might have outweighed 
the  effect  of  high  P:  D. A  decrease  in  the  mean 
particle size in nanoparticles leads to an increase 
in the release rate which could be explained on the 
basis of surface area relationship (26, 27).
Formulations  containing  E-RSPO  (Batches 
LNP3,  LNP4  and  LNP8)  followed  the  order  of 
LNP8<LNP4<LNP3  in  showing  burst  effect;  the 
difference  was  significant  for  each  possible  pair 
Figure 3. In-vitro release profiles of the prepared LMG nanosuspensions; Figure 4 (d) provides comparative in-vitro release profiles of 
the freshly prepared and stored batch of optimized nanosuspension (Bars represent standard deviation).
(P<0.05, one way ANOVA). LNP3 having Tween 
as  stabilizer  showed  exceptionally  higher  burst 
effect and 83% of drug was released within 4 hrs. 
Its lowest P: D (4: 1) and particle size (53 nm) might 
also have contributed to this effect. LNP4 and LNP8 
had  similar  P:  D  (32: 1)  but  the  latter  exhibited 
the least burst effect amongst all the batches thus 
emphasizing the superiority of PVA over poloxamer 
as stabilizer.
In-vitro drug release performed in citrate buffer pH 
4.5 did not exhibit any significant difference in terms 
of rate and extent (P>0.05, one way ANOVA; data 
not shown), thus signifying that drug release from 
the formulation was independent of pH. 
Dissolution profile modeling 
In-vitro drug release data were fitted to various 
models  and  regression  coefficient  value  (r2)  was 
calculated.  Higuchi  equation  showed  a  better  fit 
(r2>0.9) than the first-order and zero order equations. 
The values of n, as calculated by Peppas equation 
(28),  ranged  between  0.2-0.4  (<0.5)  for  all  the 
formulations,  which  is  indicative  of  Fickian  type 
of release mechanism. The results are in agreement 
to  the  one  reported  for  ciprofloxacin-Eudragit 
nanoparticles (29).
Analysis of results and statistical optimization of the 
formulation 
Formulation  could  be  evaluated  on  the  basis  of 
either  of  the  following  parameters:  particle  size, 
zeta  potential,  polydispersity  index,  entrapment 
efficiency and release properties. As compared to 
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the other parameters, particle size and EE showed 
considerable variations; therefore these parameters 
were selected as response parameters and their signal-
to-noise ratio (SNR) for each experimental run was 
determined (Table 3). “Higher the better” hypothesis 
was considered for %EE since its high value assures 
that maximum quantity of drug is restrained within 
the  matrix.  For  particle  size,  “lower  the  better” 
hypothesis  was  adopted  with  the  assumption  that 
better tissue penetration and cellular uptake could be 
achieved with the NPs of sufficiently low particle 
size (30). 
It was concluded that the least particle size could be 
attained at the factor setting; A1B3C3D2 and stabilizer 
type was its most powerful determinant. Highest EE 
could be obtained at A3B1C1D1 signifying that both 
of these responses can not have their desired values 
at the same varaible setting. ANOVA results along 
with  R  value  suggested  that  stabilizer  type  was 
highly significant in determining particle size with 
a P value of 0.006 at 95% confidance level, while 
polymer  type  was  insignificant  at  the  same  level 
(31).  Thus,  other  three  factors  can  be  arbitrarily 
assigned  level  settings  without  having  signiicant 
effect  on  the  response.  Factors A  and  B,  with  P 
values  of  0.008  and  0.018  respectively  at  95% 
confidence level, were found to have their highest 
effects  on  EE  (Table  4). Therefore,  level  settings 
C3D2 and A3B1 are of significant importance for the 
size and EE, respectively. Size of the nanoparticles 
was considered to be a relatively more important 
response  parameter  and  therefore  it  was  selected 
to  prepare  the  stastically  optimized  formulation. 
Formulation, prepared in triplicate, was subjected to 
stability, DSC and SEM studies in addition to other 
evaluations (data not given).
SEM and stability studies 
SEM  microphotographs  showed  the  presence  of 
definite and regular nanoparticles, mostly spherical 
in shape and with no sign of aggregation (Fig. 4). 
Furthurmore, they showed a homogeneous matrix 
with little evidence of crystals on the surface. Fig. 
4 b confirmed the size range of nanoparticles in the 
range of 214-218 nm. Upon storage, particle size 
increased from 480 to 683 nm and EE reached to 
Factors Signal-to-noise ratio
Particle size Entrapment efficiency
-1 0 +1 R 
value -1 0 +1 R 
value
Amount of polymer -43.41 -45.10 -45.73 2.32 35.75 37.13 38.15 2.40
Amount of drug -45.76 -44.84 -43.64 2.12 37.91 37.12 35.99 1.92
Stabilizer type  -51.04 -47.48 -35.72 15.32 37.33 37.04 36.65 0.68
Polymer type -44.22 -43.81 -46.21 2.40 37.16 36.77 37.09 0.39
Table 3. SN ratio for the response parameters at different levels
Factors DoF SS V %contribution F  P
A) Particle size
Amount of polymer (2) (7004) (3502.0) 4.1005 Pooled
Amount of drug (2) (5237) (2618.5) 3.066 Pooled
Stabilizer type  2 140039 70019.5 81.98 22.88 0.006
Polymer type 2 18528 9264.1 10.84 3.03 0.158
Pooled error (4) (12241) (6120.5)
Total 8 170808 100
B) Entrapment efficiency
Amount of polymer 2 553.134 276.567 57.71 20.29 0.008
Amount of drug 2 350.652 175.326 36.59 12.86 0.018
Stabilizer type  (2) (35.405) (17.703) 3.69 Pooled
Polymer type (2) (19.122) (9.561) 1.99 Pooled 
Pooled error (4) (54.527) (27.264)
Total 8 958.314 100
Table 4. ANOVA table for the response parameters
DoF; degree of freedom, SS; sum of squares, V; variance7 Investigation of formulation variables affecting the properties of lamotrigine nanosuspension 
82.31%. The crystal growth may be due to Ostwald 
ripening and can be avoided by a careful choice of 
surfactant (18). The decrease in EE may be attributed 
to  the  movement  of  drug  from  the  matrix  to  the 
surface under the influence of temperature. However, 
electrophoretic  behaviour  of  the  formulation  did 
not change significantly (data not shown). Stored 
formulation showed a slightly higher burst release as 
compared to the freshly prepared batch. The release 
was, however, controlled thereafter for the whole 
period of the study (Fig. 3 d).
CONCLUSION
LMG  loaded  eudragit  nanosuspensions  were 
successfully  prepared  using  emulsification-
solvent  diffusion  method.  Properties  of  prepared 
nanosuspensions  in  terms  of  size,  zeta  potential, 
PDI,  EE,  drug  content  and    in-vitro  drug  release 
were  consistent  and  within  their  acceptable  ranges. 
As  evidenced  form  statistical  analysis,  size  of  the 
nanoparticles was most strongly affected by stabilizer 
type while EE was influenced by the drug-to-polymer 
ratio.  Release  rate  seemed  to  be  governed  by  rate 
of  diffusion  of  drug  from  polymeric  matrix.  The 
formulation remained reasonably stable up to 3 months 
under  stressed  storage  conditions.  In-vivo  studies, 
proposed in future, will establish its potential as an 
alternative to the existing conventional formulations. 
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